10 February 2006

Contents

Conference reports

• 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 16-19 December 2005, Washington, USA

• Understanding TMC114 power against resistant HIV

• New antiretroviral compounds at ICAAC: new PI brecanavir from GSK; maturation inhibitor PA-457; antiviral activity of monoclonal antibody; TNX-355 in treatment experienced patients

• Comparison of pharmacokinetics of originator and generic liquid formulations and split tablets in Malawian children

• African-Americans in ACTG 5095 had shorter time to virologic failure and grade 3/4 side effects

• Predictors of insulin resistance in first year of therapy

• Three measures confirm 144-week renal record of tenofovir

• Low rash risk with efavirenz after nevirapine rash